NCT02514473View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

PHASE3CompletedINTERVENTIONAL

Enrollment

206

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-809

DRUG

Placebo

DRUG

VX-770

Trial Locations (53)

Unknown

Birmingham

Los Angeles

Palo Alto

Aurora

Wilmington

Orlando

Atlanta

Chicago

Iowa City

Boston

Minneapolis

Kansas City

Omaha

Manchester

Chapel Hill

Cincinnati

Cleveland

Dayton

Philadelphia

Pittsburgh

Charleston

Salt Lake City

Colchester

Charlottesville

Norfolk

Richmond

Seattle

Madison

Milwaukee

Herston

New South Wales

Parkville

Subiaco

Westmead

Brussels

Leuven

Vancouver

Toronto

Montreal

Copenhagen

Bordeaux

Bron

Paris

Berlin

Cologne

Giessen

Hanover

Munich

Stockholm

Edinburgh

Leeds

Belfast

London

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02514473 - A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation | Biotech Hunter | Biotech Hunter